A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 10 Mar 2017
At a glance
- Drugs Pfs25 malaria vaccine MVI (Primary) ; Aluminium hydroxide
- Indications Malaria
- Focus Adverse reactions
- 10 May 2016 Treatment arms changed from 1 arm to 4 arms with different doses of vaccine.
- 10 May 2016 Status changed from active, no longer recruiting to completed.
- 05 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.